Dexcom
DXCM
$84.41
+0.13%
DexCom, Inc. designs and commercializes continuous glucose monitoring (CGM) systems for people with diabetes, selling its sensors, transmitters, and receivers through medical equipment distributors and retail pharmacies, and increasingly integrating its hardware with automated insulin delivery (AID) pumps from partners such as Insulet and Tandem. The company is the clear category leader in CGM alongside Abbott, and its competitive identity rests on a razor-and-blade recurring-revenue model, a deep sensor-technology moat, and a widening consumer-health franchise built around its over-the-counter Stelo product. The current investor narrative centers on a growth re-acceleration story: revenue rose 13.1% year over year in the June 2026 quarter to $1.308 billion, gross margin expanded to 63.4%, and the FDA's June 2026 clearance of Stelo for pediatric use materially enlarges the addressable market into a younger, prediabetes-leaning demographic. Bulls argue that improving margins, aggressive buybacks, and the OTC/pediatric runway justify a premium multiple, while bears point to competitive pricing pressure from Abbott's Lingo, a still-elevated short interest ratio of 4.49, and a stock that has already re-rated sharply off its lows.…
DXCM
Dexcom
$84.41
Related headlines
Investment Opinion: Should I buy DXCM Today?
Rating: Buy. The core thesis is that DexCom offers a rare combination of double-digit revenue growth (13.08% year over year), expanding gross margins (63.4%, up 650 basis points from Q1 2025), and a valuation (forward PE 27.3x, PEG 0.67) that has compressed to multi-year lows, all supported by a 'strong_buy' consensus from 25 analysts with an average target of $95.08 implying 11.4% upside. The recent 4.83% one-month pullback looks like consolidation after a 37.19% six-month run rather than a trend reversal, and the FDA's June 2026 pediatric Stelo clearance provides a fresh catalyst.
Supporting evidence is robust: revenue grew 13.08% year over year to $1.308 billion in Q2 2026, net income rose to $249.1 million (19.0% net margin) from $179.8 million (15.5%), operating income jumped to $318.3 million (24.3% operating margin), and trailing free cash flow is $1.405 billion, which comfortably funds $84.7 million of quarterly capex and $603.6 million of buybacks. Return on equity of 30.5% and a gross margin of 63.4% are exceptional for a hardware-oriented medtech business, and the PEG of 0.67 suggests the market is not yet pricing in the full earnings power of the pediatric Stelo expansion. Relative to the broader medical-devices sector, DexCom's 31.0x trailing PE and 5.56x PS are at a premium, but that premium is defensible given the recurring-revenue CGM model and the 30.5% ROE.
The biggest risks that could invalidate the thesis are competitive pressure from Abbott's Lingo, a stall in the pediatric Stelo ramp, and further multiple compression if growth decelerates. This Buy would downgrade to Hold if revenue growth decelerates below 10% or if gross margin falls below 60%, and to Sell if the stock breaks below the $79 analyst low on deteriorating fundamentals. Conversely, it would upgrade to a high-conviction Buy if the PE compresses below 25x while revenue growth holds above 13%. On balance, the stock appears undervalued relative to its own history (PE down from 90.8x in Q1 2024 to 31.0x) and fairly valued to slightly cheap relative to peers given its growth and margin profile.
Sign up to view all
DXCM 12-Month Price Forecast
DexCom presents a compelling risk/reward for investors willing to tolerate above-market volatility (beta 1.419), with the bull case supported by accelerating revenue, expanding margins, and a valuation that has compressed to multi-year lows. The 0.67 PEG and 27.3x forward PE suggest the market is not fully pricing in the pediatric Stelo opportunity, while the 'strong_buy' consensus and 11.4% upside to the average target reinforce the constructive setup. The main risk is competitive pressure from Abbott's Lingo, which is explicitly reflected in the $79 analyst low target and the 4.49 short interest ratio. I would upgrade to high confidence if Q3 2026 revenue growth exceeds 15% with gross margin above 64%, and downgrade to neutral if revenue growth falls below 10% or gross margin drops below 60%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dexcom's 12-month outlook, with a consensus price target around $96.23 and implied upside of +14.0% versus the current price.
Average Target
$96.23
0 analysts
Implied Upside
+14.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $115
Analyst target range
Coverage is broad and bullish: 25 analysts cover DexCom, the consensus recommendation is "strong_buy" with a recommendation mean of 1.32 (where 1.0 is a strong buy), and the average price target is $95.08. Against the current price of $85.36, that implies roughly +11.4% upside to the consensus target, and the sentiment is reinforced by a recent institutional ratings stream that is uniformly positive — Truist, TD Cowen, Argus, Canaccord, Benchmark, Stifel, Citigroup, and RBC all carry Buy/Outperform/Overweight ratings, with the most recent actions in September 2026 reiterating rather than downgrading. The consensus therefore leans clearly bullish, and the absence of any Sell or Hold actions in the recent ratings data suggests analysts see the recent 4.8% one-month pullback as a buying opportunity rather than a warning. The target range runs from a low of $79.00 to a high of $115.00, a spread of $36 (about 38% of the average target) that signals meaningful dispersion in expectations. The high target of $115 implies roughly 35% upside and likely assumes successful pediatric/OTC Stelo scaling, continued gross-margin expansion toward the mid-60s, multiple re-rating back toward the mid-30s PE, and possibly new AID or hospital-channel catalysts; the low target of $79 implies about 7.4% downside and prices in competitive share loss, pricing pressure from Abbott's Lingo, or slower OTC adoption. The tight clustering of recent ratings around Buy, combined with the wide price-target spread, tells a nuanced story: analysts agree on direction but disagree sharply on magnitude, which is typical for a stock whose thesis hinges on a new-product ramp. With 25 analysts and a strong_buy consensus, coverage is deep enough to support efficient price discovery, and the $95.08 average target sits comfortably above the current $85.36 price, reinforcing the constructive setup.
Bulls vs Bears: DXCM Investment Factors
The bull case currently has stronger evidence: revenue is growing at 13.08% with gross margins expanding 650 basis points, net income is inflecting sharply, and the stock trades at a PEG of 0.67 with a 'strong_buy' consensus and 11.4% upside to the average target. The bear case rests on a premium multiple versus device peers, Abbott's Lingo competitive threat, and a 4.49 short interest ratio that reflects real skepticism. The single most important tension is whether the pediatric Stelo ramp can sustain the margin expansion and revenue re-acceleration that justify the premium multiple — if it can, the de-rating from 90.8x to 31.0x PE looks like a value opportunity; if competitive pressure stalls the ramp, the stock could re-test the $79 analyst low or worse. With a beta of 1.419, position sizing should be scaled down accordingly, and the recent 4.83% one-month pullback looks more like consolidation after a 37.19% six-month run than a trend reversal.
Bullish
- Revenue growth accelerating with margin expansion: Q2 2026 revenue of $1.308 billion rose 13.08% year over year from $1.157 billion, while gross margin expanded roughly 650 basis points from 56.9% in Q1 2025 to 63.4% in Q2 2026. This combination of double-digit top-line growth and improving profitability signals operating leverage that should flow disproportionately to earnings as the Stelo pediatric rollout scales.
- Profitability inflecting sharply: Q2 2026 net income of $249.1 million (19.0% net margin) versus $179.8 million (15.5%) a year ago, with operating income jumping to $318.3 million (24.3% operating margin) from $212.6 million (18.4%). Trailing return on equity of 30.5% and operating margin of 19.6% demonstrate exceptional capital efficiency for a hardware-oriented medtech business.
- Valuation near multi-year lows: The trailing PE of 31.0x and forward PE of 27.3x compare to 47.4x in Q2 2025 and 90.8x in Q1 2024, while the PS ratio has fallen from 29.6x to 5.56x. The PEG ratio of 0.67 (below 1.0) suggests the multiple is cheap relative to expected EPS growth, with consensus 2027 EPS of about $5.05.
- Strong analyst consensus with upside: 25 analysts cover DexCom with a 'strong_buy' consensus (recommendation mean 1.32) and an average price target of $95.08, implying roughly 11.4% upside from the current $85.36. Recent ratings from Truist, TD Cowen, Argus, Canaccord, Benchmark, Stifel, Citigroup, and RBC are uniformly positive, with no Sell or Hold actions.
Bearish
- Premium valuation versus device peers: The trailing PE of 31.0x and PS of 5.56x sit at a premium to the typical large-cap medical-device peer, which often trades in the high-teens to low-20s PE range. This premium is defensible only if the pediatric Stelo ramp and margin expansion continue without interruption.
- Competitive pricing pressure from Abbott: Abbott's Lingo OTC glucose monitor represents a direct competitive threat in the consumer CGM market, and the analyst low target of $79.00 (about 7.4% downside) explicitly prices in competitive share loss and pricing pressure. The wide $36 spread between the low and high targets signals meaningful disagreement on how much share DexCom can defend.
- Elevated short interest and volatility: A short interest ratio of 4.49 indicates a meaningful cohort of investors betting against the stock, while the beta of 1.419 makes DexCom roughly 42% more volatile than the market. The 32.1% maximum drawdown shows the stock is capable of sharp corrections when sentiment shifts.
- Recent momentum divergence: The shares are down 4.83% over the past month versus a 0.59% gain for SPY, producing a relative-strength reading of -5.42%. This short-term divergence from the positive 1-year trend (+28.48%) suggests the recent run may be losing steam and could foreshadow a deeper consolidation.
DXCM Technical Analysis
DexCom is in a sustained recovery uptrend: the shares are up 28.48% over the past year and 28.28% year-to-date, with the current price of $85.36 sitting at roughly 81% of the 52-week range (low $54.11, high $92.59). That positioning — well above the midpoint but still about 7.8% below the 52-week high — signals a stock with strong momentum that has not yet become fully overextended, leaving room to challenge prior highs. The 37.19% six-month gain confirms the trend is durable rather than a brief spike, and the 32.1% maximum drawdown shows the recovery was earned through a meaningful prior correction rather than a straight line up. Recent momentum, however, has cooled: the shares are down 4.83% over the past month versus a 0.59% gain for SPY, producing a relative-strength reading of -5.42% and a clear short-term divergence from the positive 1-year trend. The 3-month change of +19.80% and 6-month change of +37.19% show the intermediate trend remains firmly positive, so the 1-month pullback looks more like consolidation/mean reversion after a sharp run than a trend reversal — particularly since the stock is still up 19.8% over three months even after the recent fade. Key levels are well defined: support sits near the $79–$80 area (the analyst low target and prior breakout zone) with the 52-week low at $54.11 as the ultimate floor, while resistance is the 52-week high of $92.59. A breakout above $92.59 would confirm the uptrend and likely open a move toward the $95–$115 analyst range, whereas a breakdown below $79 would threaten the intermediate trend and put the $70s back in play. With a beta of 1.419, DexCom is roughly 42% more volatile than the market, meaning position sizing should be scaled down accordingly and stops set wider than for a low-beta healthcare name.
Beta
1.48
1.48x market volatility
Max Drawdown
-32.1%
Largest decline past year
52-Week Range
$54-$93
Price range past year
Annual Return
+24.5%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | -0.1% | +1.0% |
| 3m | +12.6% | +2.5% |
| 6m | +31.8% | +13.9% |
| 1y | +24.5% | +15.0% |
| ytd | +26.9% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
Revenue is growing at a healthy double-digit clip: Q2 2026 revenue of $1.308 billion rose 13.08% year over year from $1.157 billion in Q2 2025, and the sequential progression from $1.036 billion (Q1 2025) to $1.192 billion (Q1 2026) to $1.308 billion (Q2 2026) shows a consistent upward trajectory with no seasonal stall. Gross profit of $830 million on that revenue base implies a 63.4% gross margin, and the multi-quarter trend is clearly improving — gross margin moved from 56.9% in Q1 2025 to 59.5% in Q2 2025 to 63.4% in Q2 2026, a roughly 650-basis-point expansion that reflects manufacturing scale, sensor-cost deflation, and a richer OTC mix. This combination of accelerating revenue and expanding gross margin is the core of the bull case, since it implies operating leverage that should flow disproportionately to earnings as the Stelo pediatric rollout scales. Profitability is robust and improving: Q2 2026 net income was $249.1 million (a 19.0% net margin) versus $179.8 million (15.5%) in the year-ago quarter, and operating income jumped to $318.3 million (24.3% operating margin) from $212.6 million (18.4%). The company is solidly profitable, with a trailing net margin of 17.9%, an operating margin of 19.6%, and a return on equity of 30.5% — a level that signals exceptional capital efficiency for a hardware-oriented medtech business. Balance-sheet and cash-flow health are strong: debt-to-equity is a modest 0.506, the current ratio is 1.88, and trailing free cash flow is $1.405 billion, which comfortably funds the $84.7 million quarterly capex and the $603.6 million of stock repurchased in Q2 2026 alone. The company generated $269.2 million of operating cash flow in Q2 2026 and holds $1.105 billion of cash, so it is self-funding and returning capital rather than dependent on external financing; the main watch item is working capital, where receivables and inventory consumed cash and the cash-conversion cycle sits near 145 days.
Quarterly Revenue
$1.3B
2026-06
Revenue YoY Growth
+13.1%
YoY Comparison
Gross Margin
63.4%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
Because DexCom is solidly profitable (Q2 2026 net income of $249.1 million), the PE ratio is the appropriate primary metric: the stock trades at a trailing PE of 31.0x and a forward PE of 27.3x, and the roughly 12% compression between the two implies the market expects meaningful EPS growth over the next year — consistent with consensus 2027 EPS of about $5.05 versus the current run-rate. The forward PE of 27.3x on a business growing revenue 13% with expanding margins is not obviously stretched, and the PEG ratio of 0.67 (below 1.0) suggests the multiple is actually cheap relative to expected growth. On the secondary metrics, the picture is more mixed: the price-to-sales ratio of 5.56x and EV/sales of 6.44x are moderate for medtech, but the price-to-book of 9.43x and EV/EBITDA of 19.4x reflect the asset-light, high-return nature of the franchise. Relative to the broader medical-devices sector, DexCom's 31.0x trailing PE and 5.56x PS sit at a premium to the typical large-cap device peer (which often trades in the high-teens to low-20s PE range), but that premium is defensible given the 30.5% ROE, 63.4% gross margin, and the recurring-revenue CGM model — few device companies combine that growth, margin, and return profile. The discount is most visible in the PEG of 0.67 and the forward PE of 27.3x, which argue the market is not yet pricing in the full earnings power of the pediatric Stelo expansion. Historically, DexCom's valuation has compressed dramatically: the PE ratio was 47.4x in Q2 2025, 63.2x in Q1 2025, and 90.8x in Q1 2024, versus 31.0x today, while the PS ratio has fallen from 29.6x (Q2 2025) and 58.4x (Q1 2024) to 5.56x now. This places the stock near the bottom of its own multi-year valuation band, which can be read two ways: either the market has permanently de-rated a maturing growth story, or the shares offer a value opportunity as earnings catch up to the multiple. Given the improving margins, buyback activity, and the 0.67 PEG, the historical context leans toward the latter interpretation, though the de-rating also reflects real competitive and reimbursement risks that investors should not dismiss.
PE
31.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~149x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on DexCom's dependence on continued growth to justify its valuation and the working-capital drag from its razor-and-blade model. Debt-to-equity is a modest 0.506 and the current ratio is 1.88, so leverage is not a near-term concern, but the cash-conversion cycle near 145 days means receivables and inventory are consuming cash even as revenue grows 13.08% year over year. The company generated $269.2 million of operating cash flow in Q2 2026 against $84.7 million of quarterly capex and $603.6 million of buybacks, leaving little room for error if growth decelerates. Gross margin, while expanding to 63.4%, remains sensitive to sensor-cost deflation and OTC mix; any reversal in either could quickly compress the 19.0% net margin that supports the current 31.0x trailing PE.
Market and competitive risks are dominated by Abbott's Lingo OTC glucose monitor, which directly threatens DexCom's consumer CGM franchise and is explicitly reflected in the $79.00 analyst low target (about 7.4% downside). The stock trades at a premium to large-cap device peers (31.0x trailing PE and 5.56x PS versus high-teens to low-20s PE for peers), so any multiple compression would be painful; the PE has already fallen from 90.8x in Q1 2024 to 31.0x today, and further de-rating is possible if growth slows. With a beta of 1.419, DexCom is roughly 42% more volatile than the market, meaning a broader sector rotation out of high-multiple healthcare names or a macro risk-off event would hit the stock disproportionately. The 4.49 short interest ratio adds fuel to downside moves, as short sellers could press their advantage if the pediatric Stelo ramp disappoints.
The worst-case scenario would be a combination of Abbott's Lingo gaining meaningful OTC share, slower-than-expected pediatric Stelo adoption, and a broader de-rating of high-multiple medtech names. In that chain of events, the stock could fall to the analyst low target of $79.00 (about 7.4% downside from $85.36) and potentially re-test the 52-week low of $54.11, which would represent a roughly 36.6% loss from the current price. The 32.1% maximum drawdown over the past year shows this magnitude of decline is not hypothetical. Investors should size positions with this downside in mind, particularly given the 1.419 beta.
FAQ
The most severe risk is competitive pressure from Abbott's Lingo OTC glucose monitor, which directly threatens DexCom's consumer CGM franchise and is reflected in the $79 analyst low target (about 7.4% downside). Second, valuation compression risk is real: the stock trades at a premium to device peers (31.0x trailing PE, 5.56x PS), and further de-rating is possible if growth slows, as evidenced by the PE falling from 90.8x in Q1 2024 to 31.0x today. Third, macro sensitivity is elevated given the beta of 1.419, meaning a sector rotation out of high-multiple healthcare names or a risk-off event would hit the stock disproportionately. Fourth, company-specific execution risk: the pediatric Stelo ramp is the linchpin of the bull case, and any disappointment could trigger a re-test of the 52-week low of $54.11, a roughly 36.6% loss from the current price. The 4.49 short interest ratio adds fuel to downside moves.
The 12-month forecast is divided into three scenarios: a base case (50% probability) targeting $92-$98, aligned with the analyst average target of $95.08, assuming revenue growth of 12-14% and gross margin holding above 62%; a bull case (30% probability) targeting $105-$115, aligned with the analyst high target, assuming pediatric Stelo adoption exceeds expectations and multiple re-rates toward the mid-30s PE; and a bear case (20% probability) targeting $70-$79, aligned with the analyst low target, assuming Abbott's Lingo gains meaningful share and Stelo adoption disappoints. The base case is most likely, with the key assumption being that revenue growth holds in the low-to-mid teens and competitive pressure remains manageable. The wide $36 spread between the low and high targets signals meaningful dispersion in expectations, typical for a stock whose thesis hinges on a new-product ramp.
DXCM appears undervalued relative to its own history and fairly valued to slightly cheap relative to peers. The trailing PE of 31.0x and forward PE of 27.3x compare to 47.4x in Q2 2025 and 90.8x in Q1 2024, while the PS ratio has fallen from 29.6x to 5.56x, placing the stock near the bottom of its multi-year valuation band. The PEG ratio of 0.67 (below 1.0) suggests the multiple is cheap relative to expected EPS growth, with consensus 2027 EPS of about $5.05. Relative to large-cap medical-device peers, which often trade in the high-teens to low-20s PE range, DXCM carries a premium, but that premium is defensible given the 30.5% ROE, 63.4% gross margin, and recurring-revenue CGM model. The market appears to be pricing in mid-teens growth and continued margin expansion, but not a full re-rating to historical multiples.
From a risk/reward perspective, DXCM offers an attractive setup for investors who can tolerate volatility. The stock trades at $85.36 with a forward PE of 27.3x and a PEG of 0.67, implying the market is not fully pricing in expected EPS growth, while the average analyst target of $95.08 implies 11.4% upside. The biggest downside risk is competitive pressure from Abbott's Lingo, which is reflected in the $79 analyst low target (about 7.4% downside) and the 4.49 short interest ratio. With a beta of 1.419, the stock is roughly 42% more volatile than the market, so position sizing should be scaled down accordingly. It is a good buy for growth-oriented investors with a 12-24 month horizon who believe the pediatric Stelo ramp will sustain margin expansion, but less suitable for conservative or income-focused investors given the lack of dividend and elevated volatility.
DXCM is best suited for a medium-to-long-term investment horizon of at least 12-24 months, given its growth stage, elevated volatility (beta 1.419), and lack of dividend (payout ratio 0%, dividend yield 0%). The stock has a 32.1% maximum drawdown over the past year and a 4.49 short interest ratio, making it prone to sharp short-term swings that could shake out traders with tight stops. Earnings visibility is moderate: the company is solidly profitable with a 19.0% net margin and $1.405 billion in trailing free cash flow, but the pediatric Stelo ramp introduces execution uncertainty that will take several quarters to resolve. Short-term trading is possible for those who can exploit the defined support near $79-$80 and resistance at $92.59, but the risk/reward favors a longer holding period to capture the full earnings power of the OTC and pediatric expansion.